We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study
Read MoreHide Full Article
AstraZeneca PLC (AZN - Free Report) announced that the phase III ELEVATE-TN study on its BTK inhibitor, Calquence (acalabrutinib), has met the primary endpoint. The late-stage study evaluated Calquence in combination with Roche’s (RHHBY - Free Report) Gazyva (obinutuzumab) for the first-line treatment of chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adult patients.
In the study, the combination of Calquence plus Gazyva demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) among treatment naive patients as compared to the chemotherapy-based combo of chlorambucil and Gazyva (standard-of-care medicines).
Moreover, Calquence as a monotherapy showed better signs that are statistically significant and clinically meaningful pertaining to PFS as compared to the chemotherapy and Gazyva regimen, thereby achieving a key secondary endpoint of the study.
Overall it was observed that Calquence monotherapy or a combined regimen with Gazyva significantly increased the duration of time when patients lived without disease progression. The company plans to present detailed results from the ELEVATE-TN study at an upcoming medical conference.
Shares of AstraZeneca have inched up 2.2% so far this year versus the industry’s dip of 0.1%.
This is the second CLL study on Calquence to have tasted success. Last month, AstraZeneca announced that the phase III ASCEND analysis evaluating Calquence for relapsed/recurrent disease setting met the primary endpoint.
Calquence is presently marketed for the treatment of relapsed or refractory mantle cell lymphoma (MCL). It is being developed in phase III programs for the larger CLL indication and AstraZeneca expects to file regulatory applications based on data from the ASCEND and ELEVATE-TN studies later this year to get an approval for CLL.
In the first quarter of 2019, Calquence generated sales of $29 million, reflecting sequential growth of 20.8%.
If approved for CLL, this would definitely help AstraZeneca gain an access to broader patient population and boost sales for this promising drug. Calquence is also being developed for other forms of blood cancers.
AbbVie’s earnings estimates have been revised 1.5% upward for 2019 and 1.3% for 2020 over the past 60 days.
Merck’s earnings estimates have moved 1.7% north for 2019 and 0.8% for 2020 over the past 60 days. The stock has rallied6.6% year to date.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study
AstraZeneca PLC (AZN - Free Report) announced that the phase III ELEVATE-TN study on its BTK inhibitor, Calquence (acalabrutinib), has met the primary endpoint. The late-stage study evaluated Calquence in combination with Roche’s (RHHBY - Free Report) Gazyva (obinutuzumab) for the first-line treatment of chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adult patients.
In the study, the combination of Calquence plus Gazyva demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) among treatment naive patients as compared to the chemotherapy-based combo of chlorambucil and Gazyva (standard-of-care medicines).
Moreover, Calquence as a monotherapy showed better signs that are statistically significant and clinically meaningful pertaining to PFS as compared to the chemotherapy and Gazyva regimen, thereby achieving a key secondary endpoint of the study.
Overall it was observed that Calquence monotherapy or a combined regimen with Gazyva significantly increased the duration of time when patients lived without disease progression. The company plans to present detailed results from the ELEVATE-TN study at an upcoming medical conference.
Shares of AstraZeneca have inched up 2.2% so far this year versus the industry’s dip of 0.1%.
This is the second CLL study on Calquence to have tasted success. Last month, AstraZeneca announced that the phase III ASCEND analysis evaluating Calquence for relapsed/recurrent disease setting met the primary endpoint.
Calquence is presently marketed for the treatment of relapsed or refractory mantle cell lymphoma (MCL). It is being developed in phase III programs for the larger CLL indication and AstraZeneca expects to file regulatory applications based on data from the ASCEND and ELEVATE-TN studies later this year to get an approval for CLL.
In the first quarter of 2019, Calquence generated sales of $29 million, reflecting sequential growth of 20.8%.
If approved for CLL, this would definitely help AstraZeneca gain an access to broader patient population and boost sales for this promising drug. Calquence is also being developed for other forms of blood cancers.
Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the large cap pharmaceuticals sector include AbbVie Inc. (ABBV - Free Report) and Merck & Co., Inc. (MRK - Free Report) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AbbVie’s earnings estimates have been revised 1.5% upward for 2019 and 1.3% for 2020 over the past 60 days.
Merck’s earnings estimates have moved 1.7% north for 2019 and 0.8% for 2020 over the past 60 days. The stock has rallied6.6% year to date.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>